I Missed the DEA’s Timely-Applicant Window. Should I Still Apply?
What might a late application accomplish, what would it cost, and what remains uncertain? Those are the questions behind the decision to apply.
Missing the DEA’s timely-applicant window does not necessarily mean a cannabis business should abandon the federal medical market. But applying now also does not give the business the same position as an operator that qualified during the initial window.
The decision turns on what the business expects registration to accomplish. Is it trying to preserve important customers, enter a new market, or prepare for a future opportunity? Those are different reasons to apply, and each needs to be weighed against the cost, uncertainty, and operational changes involved.
What does a late application accomplish before approval?
21 C.F.R. § 1301.13(a) allows an unregistered person required to register to apply at any time. It generally prohibits the activities requiring registration until the application is granted and a certificate is issued.
The April 28 final rule, § 1301.13(k)(7), created a pending-application exception for qualifying applicants within the initial 60-day window. The DEA identifies that period as April 28 through June 26, 2026. Missing it does not close the door to registration, but a later application does not obtain that exception.
Under paragraph 7 of the DEA’s timely-applicant guidance, businesses outside the timely-applicant group must obtain registration before conducting covered medical-marijuana transactions with qualifying timely applicants or registrants. A late pending application is not enough.
That creates a practical problem for a supplier whose customer is asking for federal status documentation. A submission confirmation may show that the supplier is pursuing registration. It does not make that supplier an eligible trading partner while the application is pending.
What could favor applying now?
There can still be a business reason to apply. If important customers intend to operate within the federal medical system, obtaining the appropriate registration could become necessary to retain those relationships. The same may be true of new customers the business wants to reach.
Consider a cultivator whose principal buyers are pursuing federal medical registration. The useful question is how much business might remain available after approval, whether those buyers would still need the cultivator’s product, and whether the cultivator can support that channel economically. The value depends on real customers and a workable operation.
Starting the process can also give an operator a chance to address application questions before a later business opportunity arises. That is a planning consideration, not a promise of priority, approval, or a particular processing time.
What could favor further evaluation before applying?
“Better to have it than not” leaves out the work required to get there. Application preparation, responding to the agency, reviewing operations, and making changes can consume money and management time before the business knows whether approval will follow.
The DOJ’s October 30 announcement, updated November 3, confirms that state licensure does not automatically produce federal registration. It describes pre-registration investigations and, for manufacturer and distributor applications, additional review involving inspections, production controls, and quota determinations.
The possibility of denial also needs to be part of the analysis. My articles on the Minnesota OSC and dual-use licensing, the reported D.C. OSC and self-certification objection, and the reported California rejections and OSC excerpts examine objections directed at features of those jurisdictions’ medical cannabis programs. Those concerns include dual medical and adult-use licensing and patient-certification requirements.
A business could spend time and money applying and still not obtain approval because the DEA maintains an objection to the framework under which it is licensed. Would changes to the business’s own practices address that objection? Could the applicant distinguish its circumstances or challenge the DEA’s interpretation? Or would approval depend on a change to the jurisdiction’s rules or the agency’s position?
The breadth of the DEA’s language is part of the concern. The reported D.C. OSC states that the agency cannot register any medical marijuana dispensary operating under the District’s regime. The Minnesota OSC similarly states that the DEA cannot permit any applicant operating under Minnesota’s regime into the federal system because of the state’s licensing framework. Those are objections expressed in jurisdiction-wide terms, rather than confined to a particular applicant’s conduct.
As explained in my overview of orders to show cause, an OSC proposing denial is not a final denial, and the agency’s position can be contested. But if the DEA maintains that position, an applicant could face a barrier that changes to its own business would not resolve. What is the path to approval if the agency considers the underlying program incompatible with registration?
For an operator considering restructuring, the same issue applies. Would changing entities, licenses, premises, or procedures resolve the concern, or could the business incur those costs and still face the same structural objection?
Applying now could preserve a future commercial opportunity, while further evaluation could help a business avoid changes that do not address the agency’s concerns. Waiting also has potential costs if customers move on. Which risk matters more depends on the operation, the relationships at stake, and what additional information is likely to become available.
What should the business evaluate before deciding?
- Which customers or suppliers make federal medical participation commercially important, and how much revenue or capacity depends on them?
- Which entity, location, products, and activities would the application cover?
- What evidence supports eligibility, and what questions remain about the proposed operation?
- What would preparation, implementation, and ongoing compliance cost?
- Which proposed changes are reversible, and which involve surrendering rights, moving facilities, or committing substantial capital?
- What would the business do if approval takes longer than expected or the application is denied?
- What potential future federal enforcement exposure could the business face if it continues operating outside the federal medical registration framework, and how should that risk affect the decision?
The current medical pathway also should not be confused with the broader rescheduling proceeding. The DOJ distinguishes those processes and states that the existing order does not authorize recreational marijuana. A possible future change should be treated as a planning scenario, not the foundation of today’s application decision.
The question is whether the potential value of registration justifies pursuing it under the business’s circumstances. That includes the cost, the prospects for approval, and whether there would be a viable operation on the other side.
But businesses also need to think seriously about where this is heading. As discussed in my earlier article on the supply-chain implications for nonapplicants, one possibility is that the federal commercial pathway remains medical-only. If that is the direction of travel, what would remaining outside that system mean for this business over time, both commercially and in terms of federal enforcement exposure? Would its customers, suppliers, and opportunities increasingly move toward the medical market? How might the business’s activities outside that system be treated as the DEA implements the medical registration framework?
That possibility does not establish that state adult-use markets will disappear or that every business should apply now. It does make the longer-term direction part of the decision: weighing the cost and uncertainty of pursuing registration against both the commercial consequences and potential federal enforcement exposure of continuing operations outside a federal market that stays focused on medical cannabis.
Frequently asked questions
Can a medical cannabis business still apply after June 26, 2026?
Yes. Section 1301.13(a) permits applications at any time. Whether the particular applicant qualifies for the requested registration is a separate question.
Does filing late let me keep supplying timely applicants?
Filing alone does not. The DEA’s guidance requires businesses outside the qualifying timely-applicant group to obtain registration before conducting those covered transactions.
Is there a guaranteed processing time for a late application?
The cited provisions do not provide a guaranteed approval date for a late applicant. A business plan should account for uncertainty rather than assume a particular turnaround.
Should I restructure first so the application is more likely to succeed?
That depends on the identified issue and proposed change. Would restructuring address an eligibility concern, preserve a useful option, or commit resources before the applicable standard is clear? The potential benefit, remaining uncertainty, and cost of reversing the change all belong in the analysis.
Does this mean an adult-use business should apply for medical registration?
Not automatically. The relevant question is whether the business has a viable, eligible medical operation to pursue. A medical registration is not blanket authorization for adult-use activity.
Evaluate your federal registration options
Discuss the entities, activities, and business relationships behind your registration question. Contact Ryan Kocot or schedule a consultation.
Schedule a consultationFor continuing coverage, subscribe to The Federal Cannabis File.
Attorney advertising. General information only, not legal advice. Reading this article does not create an attorney-client relationship. Ryan Kocot is admitted in California, Massachusetts, and New York. Engagements outside those states are limited to federal matters; state-law questions require appropriately admitted counsel. Federal sources reviewed as of November 16, 2026.

